Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0931320180180030180
´ëÇÑ»óºÎÀ§Àå°ü.Ç︮ÄÚ¹ÚÅÍÇÐȸÁö
2018 Volume.18 No. 3 p.180 ~ p.185
Efficacy of Ecabet Sodium for Helicobacter pylori Eradication with Sequential Therapy
So Seol

Ahn Ji-Yong
Na Hee-Kyung
Jung Kee-Wook
Lee Jeong-Hoon
Kim Do-Hoon
Choi Kee-Don
Song Ho-June
Lee Gin-Hyug
Jung Hwoon-Yong
Abstract
Background/Aims: We aimed to compare the outcomes of Helicobacter pylori eradication in patients receiving sequential therapy (ST) depending on the use of ecabet sodium (ES).

Materials and Methods: Between January to December 2015, 176 patients randomly received either ST alone (n=72) or 10-day ES therapy combined with ST (n=104). After applying the exclusion criteria, 56 patients were finally assigned to the ST-only group and 84 to the ST with ES group. We retrospectively reviewed and analyzed the H. pylori eradication rate and adverse events between the two groups.

Results: Among the 140 patients, 121 (86.4%) achieved successful H. pylori eradication and 24 (17.1%) had adverse events. Eradication was achieved in 50 patients (89.3%) in the ST-only group and in 71 patients (84.5%) in the ST with ES group (P=0.420). No significant difference in the incidence of adverse events was found between the ST-only and ST with ES groups (12.5% vs. 20.2%, respectively; P=0.234). However, the ST with ES group tended to have a higher prevalence of nausea or vomiting than the ST-only group (11.9% vs. 1.8%; P=0.050).

Conclusions: ST showed a good H. pylori eradication rate without deteriorating the adverse events regardless of adding ES.
KEYWORD
Ecabet sodium, Helicobacter pylori, Sequential therapy
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø